{
    "nctId": "NCT05900986",
    "briefTitle": "LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer",
    "officialTitle": "An Open-label, Single-arm, Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of LS301-IT in Female Patients Undergoing Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for Ductal Carcinoma in Situ (DCIS) or Stage I-II Primary Invasive Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, DCIS, Invasive Duct Carcinoma of Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Adverse Events",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* DCIS (whether or not undergoing planned SLNB) or patients with Stage I-II, primary invasive carcinoma of the breast undergoing SLNB for which the patient's primary surgical treatment is single breast partial mastectomy.\n* ECOG performance status of 0 to 2\n\nExclusion Criteria:\n\n* Contraindications for surgery.\n* Simultaneous bilateral lumpectomies and bilateral partial mastectomies.\n* History of drug-related anaphylactic reactions, including those attributed to indocyanine green (ICG) or other agents used in the study\n* Prior chemotherapy, endocrine therapy, or biologic therapy for current clinically or biopsy proven breast cancer for Period 1.\n* Open surgery in the ipsilateral breast within a period of 1 year before administration of LS301-IT.\n* History of radiation therapy to the chest.\n* The lymphatic imaging agent ICG cannot be used prior to the partial mastectomy and SLNB procedures on the day of surgery.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}